Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News| Hepatic Cell News 1.24 July 14, 2017 | |
 | |
| |
TOP STORYCholangiocytes Act as Facultative Liver Stem Cells During Impaired Hepatocyte Regeneration Researchers used two independent systems to impair hepatocyte proliferation during liver injury to evaluate the contribution of non-hepatocytes to parenchymal regeneration. [Nature] Abstract | |
| |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma Scientists identified that oncogenic activation of a top candidate RNA binding protein, negative elongation factor E (NELFE), via somatic copy-number alterations enhanced MYC signaling and promoted hepatocellular carcinoma progression. [Cancer Cell] Abstract | Graphical Abstract Reversal of Cancer Gene Expression Correlates with Drug Efficacy and Reveals Therapeutic Targets Using a systems-based approach, investigators predicted four compounds showing high potency to reverse gene expression in liver cancer and validated that all four compounds were effective in five liver cancer cell lines. [Nat Commun] Full Article Researchers showed that KDM3A contributes to liver tumor formation through the phosphatidylinositol 3-kinase (PI3K) pathway, which is often activated in hepatocellular carcinoma. [Oncogene] Abstract Scientists discovered that under low-cholesterol conditions, CD147 endocytosis is inhibited but its shedding mediated by ADAM10 is enhanced. As autophagy endows cancer cells with increased adaptability to chemotherapy, and HAb 18 (a specific antibody targeting CD147) inhibits CD147 shedding and sequential CD147-ICD enhances autophagy, they found the combination of HAb 18 and cisplatin exhibited marked antitumor efficiency. [Cell Death Dis] Full Article MicroRNA-148a Deficiency Promotes Hepatic Lipid Metabolism and Hepatocarcinogenesis in Mice miR-148a knockout mice were used to investigate the intrinsic role of miR-148a in liver physiology and hepatocarcinogenesis in mice. miR-148a downregulation was found to be correlated with poor clinical outcomes in hepatocellular carcinoma patients. [Cell Death Dis] Full Article Researchers investigated the potency of the measles virus vaccine strain Edmonston in improving adoptive CD8+NKG2D+ cells for hepatocellular carcinoma treatment. [Sci Rep] Full Article Investigators found that the growth and migration of hepatocellular carcinoma cells were enhanced by 10–100 μM NaHS and dose-dependently inhibited by 600–1000 μM NaHS. [Sci Rep] Full Article The effects of augmenter of liver regeneration on hepatic ischemia-reperfusion injury in steatotic mice were investigated. The transfection of the ALR gene into steatotic mice attenuated liver injury, inhibiting hepatic oxidative stress, increasing antioxidation capacities, promoting liver regeneration, and consequently suppressing cell apoptosis/death. [Transplantation] Abstract Scientists investigated the migration and secretory functions of bone marrow endothelial progenitor cells (BM-EPCs) in fibrotic mice liver. Endothelial progenitor cells were analysed in bone marrow, blood and liver by flow cytometry and immunofluorescence. VEGF and TGF-β were analysed in the hepatic stellate cells and BM-EPCs co-cultures using ELISAs. [Cell Prolif] Abstract | |
| |
| |
REVIEWSProbing the Unseen Structure and Function of Liver Cells Through Atomic Force Microscopy The authors reflect on the achievements of atomic force microscopy (AFM) in disclosing the cellular architecture of hepatocytes, liver sinusoidal endothelial cells, Kupffer cells, stellate cells and liver-associated natural killer cells. They present new data and provide an in-depth overview of the current AFM literature on liver cell biology. [Semin Cell Dev Biol] Abstract | Graphical Abstract Investigators summarize recent literature relating to PD-1, CTLA-4, and other inhibitory receptors in antigen-specific T cell exhaustion in viral hepatitis, including hepatitis A, B, C, and others. [Int J Mol Sci] Full Article | Graphical Abstract Visit our reviews page to see a complete list of reviews in the hepatic cell research field. | |
| |
INDUSTRY NEWSSingapore to Launch Clinical Trial Using Stem Cell Therapies to Treat Liver Cirrhosis Doctors aim to determine if autologous endothelial stem cell therapy may be able to reverse liver cirrhosis for patients who do not qualify for liver transplant. If proven successful, this stem cell therapy represents a major step forward in efforts to bring regenerative medicine to liver patients. [National University Hospital (The Straits Times Online)] Press Release Promethera Biosciences SA, announced that Health Canada has accepted its New Drug Submission of Heparesc in neonatal onset Urea Cycle Disorders for review. Heparesc is composed of cryopreserved mature human liver cells obtained from ethically donated livers. [Promethera Biosciences SA] Press Release | |
| |
POLICY NEWSMarketing of Unproven Stem Cell–Based Interventions: A Call to Action Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. The authors suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments. [Sci Transl Med] Abstract | Editorial US Lawmakers Seek $1.1 Billion Boost for the NIH The US National Institutes of Health (NIH) would see its budget rise by US$1.1 billion in 2018, to $35.2 billion, under a spending proposal released today by lawmakers in the House of Representatives. [Nature News] Editorial In a Rare Move, FDA Reverses Course on Drug Developed by CEO with Ties to Trump The Food and Drug Administration has changed its tune on an experimental drug for a deadly rare disease, withdrawing a request that the company developing it run another clinical trial. The unusual move comes after President Trump met with the company’s CEO — and promised to speed up what he called a “slow and burdensome” process for drug approvals. [STAT News] Editorial White House’s Dwindling Science Office Leaves Major Research Programs in Limbo US President Donald Trump has pledged to shrink the federal government, and he seems to be starting with science. Nearly six months after taking office, Trump has not chosen a science adviser, and the White House’s Office of Science and Technology Policy has dwindled from around 130 staff members under former president Barack Obama to 35. [Nature News] Editorial
| |
EVENTSNEW The 3rd International Conference Innovations In Cancer Research and Regenerative Medicine Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Post-Doctoral Scholarship – Chronic Viral Hepatitis (Karolinska Institutet) Postdoc or PhD Position – Cancer Research (University Medical Center Groningen) Postdoctoral Researcher – Cancer and Epigenetics (St. Anne’s University Hospital) Assistant/Associate/Full Staff – Liver Disease (Lerner Research Institute) Postdoctoral Research Associate – Liver and Pancreatic Carcinogenesis (Keck School of Medicine) Postdoctoral Associate – Gene Therapy (University of Massachusetts Medical School) Research Fellow – Cancer Research (National University of Singapore) Academic Pathologist – Liver/GI (University of Texas Southwestern Medical Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hepatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
